1. Home
  2. CHRS vs MASS Comparison

CHRS vs MASS Comparison

Compare CHRS & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • MASS
  • Stock Information
  • Founded
  • CHRS 2010
  • MASS 2012
  • Country
  • CHRS United States
  • MASS United States
  • Employees
  • CHRS N/A
  • MASS N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • MASS Medical/Dental Instruments
  • Sector
  • CHRS Health Care
  • MASS Health Care
  • Exchange
  • CHRS Nasdaq
  • MASS Nasdaq
  • Market Cap
  • CHRS 102.0M
  • MASS 84.3M
  • IPO Year
  • CHRS 2014
  • MASS 2020
  • Fundamental
  • Price
  • CHRS $1.04
  • MASS $7.42
  • Analyst Decision
  • CHRS Buy
  • MASS Buy
  • Analyst Count
  • CHRS 3
  • MASS 3
  • Target Price
  • CHRS $4.68
  • MASS $5.33
  • AVG Volume (30 Days)
  • CHRS 1.3M
  • MASS 409.4K
  • Earning Date
  • CHRS 08-07-2025
  • MASS 08-05-2025
  • Dividend Yield
  • CHRS N/A
  • MASS N/A
  • EPS Growth
  • CHRS N/A
  • MASS N/A
  • EPS
  • CHRS N/A
  • MASS N/A
  • Revenue
  • CHRS $272,251,000.00
  • MASS $63,986,000.00
  • Revenue This Year
  • CHRS N/A
  • MASS N/A
  • Revenue Next Year
  • CHRS $99.43
  • MASS $22.06
  • P/E Ratio
  • CHRS $2.44
  • MASS N/A
  • Revenue Growth
  • CHRS 19.87
  • MASS 32.85
  • 52 Week Low
  • CHRS $0.66
  • MASS $1.81
  • 52 Week High
  • CHRS $2.43
  • MASS $8.06
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 68.96
  • MASS 61.12
  • Support Level
  • CHRS $0.88
  • MASS $6.38
  • Resistance Level
  • CHRS $1.06
  • MASS $7.27
  • Average True Range (ATR)
  • CHRS 0.07
  • MASS 0.36
  • MACD
  • CHRS 0.02
  • MASS 0.04
  • Stochastic Oscillator
  • CHRS 93.38
  • MASS 94.62

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

About MASS 908 Devices Inc.

908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.

Share on Social Networks: